Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 1, 2007, Pages 61-69

  Jekerle, Veronika ^a,b   Klinkhammer, Werner ^a   Reilly, Raymond M ^b,c   Piquette Miller, Micheline ^b   Wiese, Michael ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

ABC transporters; BCRP; Daunorubicin; Mitoxantrone; Multidrug resistance; Ovarian cancer; P glycoprotein

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN A; DAUNORUBICIN; ELACRIDAR; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NOVOBIOCIN; TARIQUIDAR; TETRAHYDROISOQUINOLINE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; WK X 34; WK X 50; WK X 84; XR 9577;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL;

ANTHRANILIC ACIDS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZAMIDES; CELL LINE, TUMOR; CELL SURVIVAL; DAUNORUBICIN; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ISOQUINOLINES; MITOXANTRONE; NEOPLASM PROTEINS; P-GLYCOPROTEINS; PHTHALIC ACIDS; QUINOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAZOLIUM SALTS; THIAZOLES;

EID: 33751270193     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0244-3     Document Type: Article

References (36)

1. Allen AD, Schinkel AH (2002) Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1:427-434
2. Bates SE, Robey R, Miyake K, Ross DD, Litman T (2001) The role of half-transporter in multidrug resistance. J Bioenerg Biomembr 33:503-511
3. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302
4. Brooks T, Minderman H, O'Loughlin KL et al (2003) Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2:1195-1205
5. Calne RY, Rolles K, Thiru S et al (1979) Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet 2:1033-1036
6. Dale IL, Tuffley W, Callaghan R et al (1998) Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer 78:885-892
7. Dalton WS, Grogan TM, Meltzer PS et al (1989) Drug-resistance in a multiple myeloma and non-Hodgkin's lymphoma: detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424
8. Damiani D, Michieli M, Ermacora A et al (1998) P-glycoprotein (PGP) and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias. Haematologica 83:290-297
9. Dean M, Jojo T, Bates S (2005) Tumor stem cells and drug resistance. Nature Reviews Cancer 5:275-284
10. Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358
11. Filipits M, Suchomel RW, Zochbauer S et al (1997) Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res 3:1419-1425
12. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269
13. Gijtenbeek JM, Van den Bent MJ, Vecht CJ (1999) Cyclosporin neurotoxicity: A review. J Neurol 246:339-334
14. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602
15. Jekerle V, Klinkhammer W, Scollard DA, Breitbach K, Reilly RM, Piquette-Miller M, Wiese M. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP using radio imaging techniques Int J Cancer (in press)
16. Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer Mechanisms, reversal using modulators of MDR and the role of modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265-283
17. Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537-7552
18. Lee G, Piquette-Miller M (2001) Influence of IL-6 on MDR- and MRP-mediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol 79:876-884
19. Ling V (1995) P-glycoprotein:its role in drug resistance. Am J Med 99:31-34
20. List AF, Kopecky KJ, Willman CL et al (2001) Benefit of cyclosporin modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98:3212-3220
21. Menefee ME, Fan C, Edgerly M, Draper D, Chen C, Robey R, Balis F, Figg WD, Bates S, Fojo AT (2001) Tariquidar (XR9576) is a potent and effective P-glycoprotein (Pgp) inhibitor that can be administered safely with chemotherapy. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23(16S):3093
22. Minderman H, Suvannasankha A, O'Loughlin KL et al (2002) Flow Cytometry Analysis of Breast Cancer Resistance Protein Expression and Function. Cytometry 48:59-65
23. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle C, Plumb JA, Templeton D, Charlton P (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61(2):749-758
24. Muzzammil T, Moore MJ, Hedley D, Ballinger JR (2001) Comparison of 99mTc-Sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function. Brit J Cancer 84:367-373
25. Oza AM (2002) Clinical development of P-glycoprotein modulators in oncology. Novartis Found Symp 243:103-115
26. Pajeva IK, Globisch C, Wiese M (2004) Structure-functions relationships of multidrug resistant P-glycoprotein. J Med Chem 47:2523-2533
27. Qadir M, O'Loughlin KL, Fricke SM et al (2005) Cyclosporin A is a broad-spectrum multidrug resistance modular. Clin Cancer Res 11:2320-2326
28. Raaijmakers MH, De Grouw EP, Heuver LH et al (2005) Breast cancer resistance protein in drug resistance of primitive CD34 + 38- cells in acute myeloid leukemia. Clin Cancer Res 11:2436-2444
29. Roe M, Folkes A, Ashworth P et al (1999) Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Let 9:595-600
30. Ross DD (2000) Novel mechanisms of drug-resistance in leukemia. Leukemia 14:467-473
31. Ross DD (2004) Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Heamatol 4:641-651
32. Smeets M, Raymakers R, Muus P et al (2001) Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance. Leukemia 15:80-81
33. Tsuruo T, Lida H, Nojiri M, Tsukagoshi S, Sakurai Z (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972
34. Urasaki Y, Ueda T, Yoshida A et al (1996) Establishment of daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms. Anticancer Res 16:709-714
35. Utsunomiya K, Ballinger JR, Piquette-Miller M et al (2000) Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP- expressing tumour cell line. Eur J Nucl Med 27:1786-1792
36. Yang CH, Chen YC, Kuo ML (2003) Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. Anticancer Res 23:2519-2523